1495 related articles for article (PubMed ID: 29495962)
21. Lack of TNF-alpha receptor type 2 protects motor neurons in a cellular model of amyotrophic lateral sclerosis and in mutant SOD1 mice but does not affect disease progression.
Tortarolo M; Vallarola A; Lidonnici D; Battaglia E; Gensano F; Spaltro G; Fiordaliso F; Corbelli A; Garetto S; Martini E; Pasetto L; Kallikourdis M; Bonetto V; Bendotti C
J Neurochem; 2015 Oct; 135(1):109-24. PubMed ID: 25940956
[TBL] [Abstract][Full Text] [Related]
22. Mutant SOD1 prevents normal functional recovery through enhanced glial activation and loss of motor neuron innervation after peripheral nerve injury.
Schram S; Chuang D; Schmidt G; Piponov H; Helder C; Kerns J; Gonzalez M; Song F; Loeb JA
Neurobiol Dis; 2019 Apr; 124():469-478. PubMed ID: 30594811
[TBL] [Abstract][Full Text] [Related]
23. Regional differences in the inflammatory and heat shock response in glia: implications for ALS.
Clarke BE; Gil RS; Yip J; Kalmar B; Greensmith L
Cell Stress Chaperones; 2019 Sep; 24(5):857-870. PubMed ID: 31168740
[TBL] [Abstract][Full Text] [Related]
24. Characterizing the multiple roles of FGF-2 in SOD1
Kefalakes E; Böselt S; Sarikidi A; Ettcheto M; Bursch F; Naujock M; Stanslowsky N; Schmuck M; Barenys M; Wegner F; Grothe C; Petri S
J Cell Physiol; 2019 May; 234(5):7395-7410. PubMed ID: 30370540
[TBL] [Abstract][Full Text] [Related]
25. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex.
Thomsen GM; Gowing G; Latter J; Chen M; Vit JP; Staggenborg K; Avalos P; Alkaslasi M; Ferraiuolo L; Likhite S; Kaspar BK; Svendsen CN
J Neurosci; 2014 Nov; 34(47):15587-600. PubMed ID: 25411487
[TBL] [Abstract][Full Text] [Related]
26. Muscle-derived but not centrally derived transgene GDNF is neuroprotective in G93A-SOD1 mouse model of ALS.
Li W; Brakefield D; Pan Y; Hunter D; Myckatyn TM; Parsadanian A
Exp Neurol; 2007 Feb; 203(2):457-71. PubMed ID: 17034790
[TBL] [Abstract][Full Text] [Related]
27. Autophagy activation and neuroprotection by progesterone in the G93A-SOD1 transgenic mouse model of amyotrophic lateral sclerosis.
Kim J; Kim TY; Cho KS; Kim HN; Koh JY
Neurobiol Dis; 2013 Nov; 59():80-5. PubMed ID: 23891729
[TBL] [Abstract][Full Text] [Related]
28. Dismutase-competent SOD1 mutant accumulation in myelinating Schwann cells is not detrimental to normal or transgenic ALS model mice.
Turner BJ; Ackerley S; Davies KE; Talbot K
Hum Mol Genet; 2010 Mar; 19(5):815-24. PubMed ID: 20008901
[TBL] [Abstract][Full Text] [Related]
29. Acute glial activation by stab injuries does not lead to overt damage or motor neuron degeneration in the G93A mutant SOD1 rat model of amyotrophic lateral sclerosis.
Suzuki M; Klein S; Wetzel EA; Meyer M; McHugh J; Tork C; Hayes A; Svendsen CN
Exp Neurol; 2010 Feb; 221(2):346-52. PubMed ID: 20005223
[TBL] [Abstract][Full Text] [Related]
30. Amyloid precursor protein (APP) contributes to pathology in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.
Bryson JB; Hobbs C; Parsons MJ; Bosch KD; Pandraud A; Walsh FS; Doherty P; Greensmith L
Hum Mol Genet; 2012 Sep; 21(17):3871-82. PubMed ID: 22678056
[TBL] [Abstract][Full Text] [Related]
31. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation.
Peviani M; Salvaneschi E; Bontempi L; Petese A; Manzo A; Rossi D; Salmona M; Collina S; Bigini P; Curti D
Neurobiol Dis; 2014 Feb; 62():218-32. PubMed ID: 24141020
[TBL] [Abstract][Full Text] [Related]
32. Spinal inhibitory interneuron pathology follows motor neuron degeneration independent of glial mutant superoxide dismutase 1 expression in SOD1-ALS mice.
Hossaini M; Cardona Cano S; van Dis V; Haasdijk ED; Hoogenraad CC; Holstege JC; Jaarsma D
J Neuropathol Exp Neurol; 2011 Aug; 70(8):662-77. PubMed ID: 21760539
[TBL] [Abstract][Full Text] [Related]
33. Clemastine Confers Neuroprotection and Induces an Anti-Inflammatory Phenotype in SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis.
Apolloni S; Fabbrizio P; Parisi C; Amadio S; Volonté C
Mol Neurobiol; 2016 Jan; 53(1):518-531. PubMed ID: 25482048
[TBL] [Abstract][Full Text] [Related]
34. Microglia RAGE exacerbates the progression of neurodegeneration within the SOD1
MacLean M; Juranek J; Cuddapah S; López-Díez R; Ruiz HH; Hu J; Frye L; Li H; Gugger PF; Schmidt AM
J Neuroinflammation; 2021 Jun; 18(1):139. PubMed ID: 34130712
[TBL] [Abstract][Full Text] [Related]
35. Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis.
Jiang HQ; Ren M; Jiang HZ; Wang J; Zhang J; Yin X; Wang SY; Qi Y; Wang XD; Feng HL
Neuroscience; 2014 Sep; 277():132-8. PubMed ID: 24699224
[TBL] [Abstract][Full Text] [Related]
36. Novel behavioural characteristics of the superoxide dismutase 1 G93A (SOD1
Kreilaus F; Guerra S; Masanetz R; Menne V; Yerbury J; Karl T
Genes Brain Behav; 2020 Feb; 19(2):e12604. PubMed ID: 31412164
[TBL] [Abstract][Full Text] [Related]
37. The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1
Keerie A; Brown-Wright H; Kirkland I; Grierson A; Alix JJP; Holscher C; Mead RJ
Sci Rep; 2021 Aug; 11(1):17027. PubMed ID: 34426623
[TBL] [Abstract][Full Text] [Related]
38. Vascular endothelial growth factor prevents G93A-SOD1-induced motor neuron degeneration.
Lunn JS; Sakowski SA; Kim B; Rosenberg AA; Feldman EL
Dev Neurobiol; 2009 Nov; 69(13):871-84. PubMed ID: 19672955
[TBL] [Abstract][Full Text] [Related]
39. In-vivo effects of knocking-down metabotropic glutamate receptor 5 in the SOD1
Bonifacino T; Cattaneo L; Gallia E; Puliti A; Melone M; Provenzano F; Bossi S; Musante I; Usai C; Conti F; Bonanno G; Milanese M
Neuropharmacology; 2017 Sep; 123():433-445. PubMed ID: 28645622
[TBL] [Abstract][Full Text] [Related]
40. Pleiotropic activity of systemically delivered angiogenin in the SOD1
Crivello M; O'Riordan SL; Woods I; Cannon S; Halang L; Coughlan KS; Hogg MC; Lewandowski SA; Prehn JHM
Neuropharmacology; 2018 May; 133():503-511. PubMed ID: 29486168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
